Insulin Glargine · Basaglar Kwikpen, Lantus Solostar

What is Insulin Glargine?

Insulin glargine is a long-acting human insulin analog that binds the insulin receptor to regulate glucose metabolism. It stimulates peripheral glucose uptake by skeletal muscle and fat, inhibits hepatic glucose production, and enhances protein synthesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Basaglar Kwikpen, Lantus Solostar, Toujeo, Basaglar

Drug type

Recombinant protein

Targets

insulin receptor (INSR)

Mechanism

Agonist of insulin receptor (INSR)

Pathways

glucose uptake, glucose metabolism, protein synthesis

Therapy area

Endocrine

Developer

Sanofi Aventis Us

In trials of

LLY

FDA status

Approved as Basaglar Kwikpen, Lantus Solostar, Toujeo (April 20, 2000), BLA021081 · FDA label

✅ FDA-approved uses

• Diabetes mellitus (Toujeo)

From the indications section of the FDA label (version of May 30, 2025). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Diabetes Mellitus, Type 2

Other drugs acting on INSR

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Basaglar Kwikpen (2026-06-16), indications
• FDA label Insulin Glargine (2026-01-23), indications
• FDA label Lantus Solostar (2025-06-02), indications
• FDA label Toujeo (2025-05-30), indications
• ClinicalTrials.gov NCT06370715

Updated Oct 3, 2026.